Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Soochow UniversityNo recent work listed

Meng Shen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-2550-8651; OpenAlex author ID A5108745712. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper

Papers 10

  1. M2-phenotype tumour-associated macrophages upregulate the expression of prognostic predictors MMP14 and INHBA in pancreatic cancer. Co-author DOI 10.1111/jcmm.17191↗
  2. Author Correction: Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. Co-author DOI 10.1038/s41598-021-84394-4↗
  3. FOLFIRINOX regulated tumor immune microenvironment to extend the survival of patients with resectable pancreatic ductal adenocarcinoma. First author DOI 10.21037/gs-20-828↗
  4. Inflammation Promotes Progression of Pancreatic Cancer Through WNT/β-Catenin Pathway-Dependent Manner. Co-author DOI 10.1097/mpa.0000000000001386↗
  5. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresect… Co-author DOI 10.18632/oncotarget.21340↗
  6. Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-κB pathway dependent repression of PP2Ac. Co-author DOI 10.1080/15384101.2015.1127468↗
  7. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Co-author DOI 10.18632/oncotarget.9975↗
  8. Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. Co-author DOI 10.1038/srep11836↗
  9. FH535 inhibited metastasis and growth of pancreatic cancer cells. Co-author DOI 10.2147/ott.s82718↗
  10. Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine an… Co-author DOI 10.3892/ijo.2015.3156↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Tao · 9 shared papers, 2015–2021 · strength 0.67
  2. Mengyao Wu · 6 shared papers, 2015–2022 · strength 0.54
  3. Qiaoming Zhi · 7 shared papers, 2015–2021 · strength 0.48
  4. Mengdan Xu · 3 shared papers, 2019–2022 · strength 0.38
  5. Kai Chen · 5 shared papers, 2015–2021 · strength 0.36
  6. Mengyao Wu · 4 shared papers, 2015–2021 · strength 0.28
  7. Weiming Duan · 3 shared papers, 2015–2022 · strength 0.25
  8. Daoming Li · 3 shared papers, 2015–2021 · strength 0.22
  9. Wei Li · 2 shared papers, 2016–2021 · strength 0.18
  10. Wei Li · 3 shared papers, 2015–2017 · strength 0.16
  11. Lian Lian · 3 shared papers, 2015–2017 · strength 0.16
  12. Zhan‐Wen Liang · 1 shared paper, 2022 · strength 0.15
  13. Wei Li · 1 shared paper, 2022 · strength 0.15
  14. Wei Li · 2 shared papers, 2015 · strength 0.10
  15. Wei Li · 1 shared paper, 2019 · strength 0.08
  16. Rui Ren · 1 shared paper, 2019 · strength 0.08
  17. Xiaojie Bian · 1 shared paper, 2017 · strength 0.06
  18. Yuan Hong Gao · 1 shared paper, 2017 · strength 0.06
  19. Lu Liu · 1 shared paper, 2016 · strength 0.05
  20. Wenjie Wang · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.